Literature DB >> 16771241

Primary arteriovenous fistulas in the forearm for hemodialysis: effect of miscellaneous factors in fistula patency.

Bilgehan Erkut1, Yahya Unlü, Münacettin Ceviz, Necip Becit, Azman Ateş, Abdurrahim Colak, Hikmet Koçak.   

Abstract

BACKGROUND: The provision and maintenance of vascular access remains a major cost to end-stage renal failure programs. In addition, vascular access occlusion, results in significant morbidity in hemodialysis patients. Age, gender, diabetes mellitus, malignancy, smoking habits, administration of heparin per hemodialysis session, previous dialysis catheter insertion, number of hemodialysis sessions and location of the fistula may be associated with survival of the primary arteriovenous fistula. We examined the effects of various factors on fistulas in 412 chronic renal insufficiency patients.
METHODS: From 1995 to 2004, 412 arteriovenous fistulas were created by the Department of Cardiovascular Surgery at the Medical Faculty of Atatürk University for hemodialysis. The mean age of the patients was 45 years (range 6 to 62 years). We evaluated the effects of various factors for patency rates in the patients who had primary arteriovenous fistulas. Primary patency was defined as the duration of fistula patency without revision. Twenty-eight patients (6.7%) with ischemic cardiac disease did not require surgical interference. Analyzed data were age, gender, smoking habits, diabetes mellitus, malignant neoplasm, previous dialysis catheter insertion, number of hemodialysis sessions, and fistula location.
RESULTS: In 298 patients, where lower-arm radiocephalic fistulas were created, the fistula patency was 74.1%, 64.2%, 49.8%, 33.7%, and 4.1% after 1, 2, 3, 4, and 5 years, respectively, in the other 114 patients, where upper-arm fistulas were created, these rates were 84.0%, 72.2%, 53.3%, 39.8%, and 12.3%, respectively. There was no significantly difference between the upper-arm fistulas and the lower-arm fistulas statistically (p = 0.069). Factors affecting the primary patency of arteriovenous fistulas were diabetes mellitus (p = 0.0001), hemodialysis counts > or =3 per week (p < 0.0005), presence of malignancy (p < 0.0005), previous catheter insertion (p < 0.0007), and administration of heparin per hemodialysis session (p = 0.0008).
CONCLUSION: While primary arteriovenous fistula patency was shortened in chronic renal insufficiency patients with diabetes mellitus, presence of malignancy, and previous catheter insertion, patency was longer in patients with heparin used for hemodialysis and hemodialysis count per week (> or =3).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16771241     DOI: 10.1080/08860220600583617

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  11 in total

1.  Arteriovenous fistulas as vascular access for hemodialysis: The preliminary experience at the University Hospital of the West Indies, Jamaica.

Authors:  Shamir O Cawich; Hilary Brown; Allie Martin; Mark S Newnham; Rageev Venugopal; Eric Williams
Journal:  Int J Angiol       Date:  2009

2.  Anesthetic choice for arteriovenous access creation: A National Anesthesia Clinical Outcomes Registry analysis.

Authors:  Kaitlin Woods; Samantha D Minc; Dylan Thibault; Jacob Lambert; Amaris Jalil; Luke Marone; Matthew Ellison; Jw Awori Hayanga; Heather K Hayanga
Journal:  J Vasc Access       Date:  2021-09-21       Impact factor: 2.326

3.  Improved treatment feasibility in children with hemophilia using arteriovenous fistulae: the results after seven years of follow-up.

Authors:  Maria Elisa Mancuso; Luisa Berardinelli; Claudio Beretta; Mauro Raiteri; Ermanno Pozzoli; Elena Santagostino
Journal:  Haematologica       Date:  2009-03-13       Impact factor: 9.941

4.  Early follow-up results of arteriovenous fistulae created for hemodialysis.

Authors:  Hikmet Iyem
Journal:  Vasc Health Risk Manag       Date:  2011-05-19

5.  Association Between Vascular Access Dysfunction and Subsequent Major Adverse Cardiovascular Events in Patients on Hemodialysis: A Population-Based Nested Case-Control Study.

Authors:  Te-Hui Kuo; Chien-Tzu Tseng; Wei-Hung Lin; Jo-Yen Chao; Wei-Ming Wang; Chung-Yi Li; Ming-Cheng Wang
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

6.  Hyperphosphatemia is associated with patency loss of arteriovenous fistula after 1 year of hemodialysis.

Authors:  Ju-Young Moon; Hyae Min Lee; Sang-Ho Lee; Tae-Won Lee; Chun-Gyoo Ihm; Young-Il Jo; Sang-Woong Han; Sug-Gyun Shin
Journal:  Kidney Res Clin Pract       Date:  2015-02-23

7.  Native arterio-venous fistula is the vascular access of choice for hemodialysis in end stage renal disease.

Authors:  Farooq Ahmad Ganie; Hafeezulla Lone; Abdul Majeed Dar; Ghulam Nabi Lone; Mohd Lateef Wani
Journal:  Int Cardiovasc Res J       Date:  2013-06-01

8.  The association of erythropoietin-stimulating agents and increased risk for AV-fistula dysfunction in hemodialysis patients. A retrospective analysis.

Authors:  Anna Wärme; Henrik Hadimeri; Salmir Nasic; Bernd Stegmayr
Journal:  BMC Nephrol       Date:  2021-01-18       Impact factor: 2.388

9.  Type of arteriovenous vascular access and association with patency and mortality.

Authors:  Gürbey Ocak; Joris I Rotmans; Carla Y Vossen; Frits R Rosendaal; Raymond T Krediet; Elisabeth W Boeschoten; Friedo W Dekker; Marion Verduijn
Journal:  BMC Nephrol       Date:  2013-04-04       Impact factor: 2.388

10.  Endovascular Arteriovenous Dialysis Fistula Intervention: Outcomes and Factors Contributing to Fistula Failure.

Authors:  Edwin A Takahashi; William S Harmsen; Sanjay Misra
Journal:  Kidney Med       Date:  2020-04-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.